Eledon Pharmaceuticals Announces Participation in November Conferences
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that members of management will be participating in two upcoming virtual investor conferences in November.
| Event: | Guggenheim 3rd Annual Neuro/Immunology Conference (November 15-16) |
| Format: | 1x1 Meetings |
| Event: | Jefferies London Healthcare Conference (November 18-19) |
| Format: | Available on Demand Presentation and 1x1 Meetings |
| Date: | Thursday, November 18, 2021 |
| Time: | Available on-demand starting at 3:00 AM ET |
| Location: |
Replay Link:
A replay will be accessible for 90 days following the live session on the Events page of the Investors section on the Company’s website at .
If you are interested in arranging a one-on-one meeting virtually on either November 18th or 19th, please contact your Jefferies representative. For more information about the Jefferies London Healthcare Conference, please visit the Jefferies .
About Eledon Pharmaceuticals and AT-1501
Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at .
Follow Eledon Pharmaceuticals on social media: ;
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
